ArticleCell reports2018
Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 67 citations in OpenAlex.
- Intra-Islet Paracrine Regulation of Glucagon Secretion During Hypoglycemia, Euglycemia, and Hyperglycemia.Annals of the New York Academy of Sciences · 2026Review
- Glucagon receptor blockade protects spermatogenesis by enhancing PFKFB3-mediated lactate production in Sertoli cells.Journal of translational medicine · 2026Article
- Discovery of Biased Dual-Agonists of Glucagon-Like Peptide 1 and Glucagon Receptors through Mutation of a Conserved Aspartate.ACS medicinal chemistry letters · 2026Article
- Modulation of the gut-heart axis by exercise in diabetic cardiomyopathy: Microbial mechanisms and clinical implications.iScience · 2026Review
- Bridging the Gap Between Static Histology and Dynamic Organ-on-a-Chip Models.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Prolonged glucagon exposure rewires lipid oxidation and drives diabetic kidney disease progression.Nature communications · 2025Article
- Loss of hepatic autophagy induces α-cell proliferation through impaired glutamine-dependent gluconeogenesis.Physiological reports · 2025Article
- The neglected PCK1/glucagon (inter)action in nutrient homeostasis beyond gluconeogenesis: Disease pathogenesis and treatment.Molecular metabolism · 2025Review
- SPTLC3 regulates plasma membrane sphingolipid composition to facilitate hepatic gluconeogenesis.Cell reports · 2024Article
- GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms.The Journal of endocrinology · 2024Review
- Cardiovascular adaptations and pathological changes induced by spaceflight: from cellular mechanisms to organ-level impacts.Military Medical Research · 2024Review
- Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction.Circulation research · 2024Article
- Impaired Fat Absorption from Intestinal Tract in High-Fat Diet Fed Male Mice Deficient in Proglucagon-Derived Peptides.Nutrients · 2024Article
- Ceramides are fuel gauges on the drive to cardiometabolic disease.Physiological reviews · 2024Review
- GLP-1 metabolite GLP-1(9-36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion.Diabetologia · 2024Article
- An orally available compound suppresses glucagon hypersecretion and normalizes hyperglycemia in type 1 diabetes.JCI insight · 2024Article
- Fatty acid β-oxidation and mitochondrial fusion are involved in cardiac microvascular endothelial cell protection induced by glucagon receptor antagonism in diabetic mice.Journal of diabetes · 2023Article
- Distinct physiological characteristics and altered glucagon signaling in GHRH knockout mice: Implications for longevity.Aging cell · 2023Article
- Glucagon and Its Receptors in the Mammalian Heart.International journal of molecular sciences · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Ankit X SharmaTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Ezekiel B Quittner-StromTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Young LeeTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA; Medical Service, Veteran's Administration North Texas Health Care System, Dallas, TX 75216, USA.
Joshua A JohnsonTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Sarah A MartinDepartment of Molecular Genetics, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Xinxin YuTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA; Medical Service, Veteran's Administration North Texas Health Care System, Dallas, TX 75216, USA.
Jianping LiDivision of Cardiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
John LuREMD Biotherapeutics Inc., Camarillo, CA 93012, USA.
Zheqing CaiCardio-lab, Baltimore, MD 21205, USA.
Shiuhwei ChenTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
May-Yun WangTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA; Medical Service, Veteran's Administration North Texas Health Care System, Dallas, TX 75216, USA.
Yiyi ZhangTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Mackenzie J PearsonTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Andie C DornTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Jeffrey G McDonaldDepartment of Molecular Genetics, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA; Center for Human Nutrition, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Ruth GordilloTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Hai YanREMD Biotherapeutics Inc., Camarillo, CA 93012, USA.
Dung ThaiREMD Biotherapeutics Inc., Camarillo, CA 93012, USA.
Zhao V WangDivision of Cardiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Roger H UngerTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA; Medical Service, Veteran's Administration North Texas Health Care System, Dallas, TX 75216, USA.
William L HollandTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA. Electronic address: will.holland@hsc.utah.edu.
The University of Texas Southwestern Medical Center · US
Funding
DIVISION OF CELL &MOLECULAR BIOLOGY TRAINING PROGRAMT32GM008203 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI COBB, MELANIE H. · 1987 to 2018
$7.0MLiver-islet and intra-islet cross talk in alpha cell hyperplasia and beta cell regenerationR01DK112826 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HOLLAND, WILLIAM L · 2017 to 2025
$3.4MSphingolipid-Mediated Dysregulation of Glucose and Energy Homeostasis in the CNSR01DK108833 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HOLLAND, WILLIAM L · 2016 to 2020
$1.8MAssessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetesR42DK108305 · NIDDK · REMD BIOTHERAPEUTICS, INC. · PI KLEIN, SAMUEL, THAI, DUNG L · 2016 to 2018
$1.7MAdiponectin Receptors and S1P Signaling in Beta Cell Survival and ProliferationK99DK094973 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HOLLAND, WILLIAM L · 2012 to 2013
$178kSphingolipid-mediated dysregulation of glucose and energy homeostasis by POMC neuronsF30DK108534 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI JOHNSON, JOSHUA · 2015 to 2017
$93kElucidating the function of TM6SF2F32DK112529 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN, SARAH ASHLEY · 2017 to 2018
$74kNIDDK NIH HHS F30 DK108534NIDDK NIH HHS F32 DK112529NIDDK NIH HHS K99 DK094973NIDDK NIH HHS R01 DK108833NIDDK NIH HHS R01 DK112826NIDDK NIH HHS R42 DK108305NIGMS NIH HHS T32 GM008203
Abstract
The antidiabetic potential of glucagon receptor antagonism presents an opportunity for use in an insulin-centric clinical environment. To investigate the metabolic effects of glucagon receptor antagonism in type 2 diabetes, we treated Lepr
Indexed as
Adenylate KinaseAnimalsAntibodies, MonoclonalDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diabetic CardiomyopathiesDisease Models, AnimalEnzyme ActivationGluconeogenesisGlucoseGlucose Tolerance TestHeartHyperglycemiaInsulinLipid MetabolismLipidsAdenylate KinaseAntibodies, MonoclonalGlucoseInsulinLipidsReceptors, Glucagonadiponectinceramidelipotoxicitysphingolipid
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.